Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.51 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11889090 | 0.82 | CA12 (0.51) | CA12CA4CA7CA9CA14 | |
| SCHEMBL3655465 | 0.81 | CA12 (0.74) | CA12CA4CA7CA9CA14 | |
| SCHEMBL29908813 | 0.80 | BCHE (0.49) | CA12CA4CA7CA9CA14 | |
| SCHEMBL7476439 | 0.80 | NCEH1 (0.44) | NCEH1CYP1A1CYP1B1TSHRALDH1A1 | |
| SCHEMBL16239187 | 0.78 | HSP90AA1 (0.49) | CA12CA4CA7CA9CA14 | |
| SCHEMBL20563202 | 0.78 | MTNR1A (0.54) | NCEH1CYP1A1CYP1B1MTNR1A | |
| SCHEMBL30094492 | 0.78 | NCEH1 (0.46) | CA12CA4CA7CA9CA14 | |
| SCHEMBL27972316 | 0.77 | NCEH1 (0.43) | CA12CA4CA7CA9CA14 | |
| SCHEMBL16238914 | 0.75 | TSHR (0.47) | NCEH1TSHRALDH1A1HSD17B10CYP1A2 | |
| SCHEMBL17883929 | 0.75 | NCEH1 (0.41) | CA12CA4CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434207-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-09-06 | — | — | US | disclosed |
| CN-108863959-B | P2X4 receptor antagonists | 日本化学药品株式会社 | 2021-11-30 | — | — | CN | disclosed |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-07-16 | — | — | US | disclosed |
| CN-111333588-A | P2X4 receptor antagonists | 日本化学药品株式会社 | 2020-06-26 | — | — | CN | disclosed |
| US-10633349-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-04-28 | — | — | US | disclosed |
| CN-104066724-B | P2X4 receptor antagonists | 日本化学药品株式会社 | 2020-04-17 | — | — | CN | disclosed |
| CN-110483423-A | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO | 2019-11-22 | — | — | CN | disclosed |
| CN-108863959-A | P2X4 RECEPTOR ANTAGONIST | 日本化学药品株式会社 | 2018-11-23 | — | — | CN | disclosed |
| US-20180201587-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2018-07-19 | — | — | US | disclosed |
| US-9969700-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD. (JP) | 2018-05-15 | — | — | US | disclosed |
| EP-2803662-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20160280667-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2016-09-29 | — | — | US | disclosed |
| US-20140357858-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2014-12-04 | — | — | US | disclosed |
| EP-2803662-A1 | P2X4 RECEPTOR ANTAGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2014-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280667-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | CA12 3265/4885CA4 1722/4885CA7 1931/4885 |
| US-20140357858-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | CA12 3280/4885CA4 1670/4885CA7 1922/4885 |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | CA12 3280/4885CA4 1670/4885CA7 1922/4885 |
| US-11434207-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | CA12 3280/4885CA4 1670/4885CA7 1922/4885 |
| US-10633349-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | CA12 3280/4885CA4 1670/4885CA7 1922/4885 |
| US-20180201587-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | CA12 3280/4885CA4 1670/4885CA7 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.